Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.
Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Organogenesis Holdings Inc. (Nasdaq: ORGO) has announced significant leadership changes within its Board of Directors. Gary S. Gillheeney, Sr. has been elected as Chair of the Board while continuing as President and CEO, a role he has held since 2014, succeeding Alan A. Ades, who remains a director. Additionally, Arthur S. Leibowitz, a director since 2018, has been appointed as Lead Independent Director. The Board expressed confidence in Gillheeney's leadership and strategic vision, which are expected to drive the company’s growth in the Advanced Wound Care and Surgical and Sports Medicine markets. The company's commitment to integrated healing solutions aims to improve patient outcomes and reduce care costs. However, forward-looking statements indicate potential risks related to competition, reimbursement levels, and product viability.